Savvy Stock Picks

ARM Holdings plc (ADR) (Public, NASDAQ:ARMH) decreased -1.37%, to close at $20.15 and its overall traded volume was 2.74M shares during the last session against its average volume of 2.74M. ARMH opened the day at $20.05, it made an intraday low of $19.94 and an intraday high of $20.23. The stock has a 52 week low of $8.21 and 52 week high of $21.03. ARMH’s market capitalization is 8.88B and it has 440.60M outstanding shares.

About ARM Holdings plc (ADR) (Public, NASDAQ:ARMH)

ARM Holdings plc (ARM) designs microprocessors, physical Internet protocol (IP) and related technology and software, and sells development tools. ARM licenses and sells its technology and products to international electronics companies, which in turn manufacture, market and sell microprocessors, application-specific integrated circuits (ASICs) and application-specific standard processors (ASSPs) based on ARM’s technology to systems companies for incorporation into a variety of end products. ARM also licenses and sells development tools directly to systems companies and provides support services to its licensees, systems companies and other systems designers. ARM’s principal geographic markets are Europe, the United States and Asia Pacific. It operates in three segments: Processor Division (PD), Physical IP Division (PIPD) and Systems Design Division (SDD).

Seagate Technology PLC (Public, NASDAQ:STX) decreased -0.34%, to close at $14.80 and its overall traded volume was 2.72M shares during the last session against its average volume of 12.75M. STX opened the day at $14.77, it made an intraday low of $14.76 and an intraday high of $14.87. The stock has a 52 week low of $9.84 and 52 week high of $21.58. STX’s market capitalization is 7.00B and it has 472.69M outstanding shares.

About Seagate Technology PLC (Public, NASDAQ:STX)

Seagate Technology plc (Seagate) designs, manufactures, markets and sells hard disk drives. The Company produces a range of disk drive products addressing enterprise applications, where its products are primarily used in enterprise servers, mainframes and workstations; client compute applications, where its products are used in desktop and notebook computers; and client non-compute applications, where its products are used in a variety of devices, such as digital video recorders (DVRs), and other consumer electronic devices, such as personal data backup systems, portable external storage systems and digital media systems. The Company sells its disk drives primarily to major original equipment manufacturers (OEMs), distributors and retailers. In addition to manufacturing and selling disk drives, the Company provides storage services for small- to medium-sized businesses, including online backup, data protection and recovery solutions.

Whitney Holding Corp. (Public, NASDAQ:WTNY) decreased -4.21%, to close at $13.41 and its overall traded volume was 2.71M shares during the last session against its average volume of 1.11M. WTNY opened the day at $13.96, it made an intraday low of $13.40 and an intraday high of $14.15. The stock has a 52 week low of $7.04 and 52 week high of $15.29. WTNY’s market capitalization is 1.30B and it has 96.64M outstanding shares.

About Whitney Holding Corp. (Public, NASDAQ:WTNY)

Whitney Holding Corporation (Whitney) is a bank holding company. The Company is the parent of Whitney National Bank (the Bank). The Bank is a national banking association. The Company, through the Bank, engages in community banking activities and serves a market area that covers the five-state Gulf Coast region stretching from Houston, Texas, across southern Louisiana and the coastal region of Mississippi, to central and south Alabama, the western panhandle of Florida, and to the Tampa Bay metropolitan area of Florida. The Bank also maintains a foreign branch on Grand Cayman in the British West Indies. The Bank provides a range of community banking services to commercial, small business and retail customers, offering a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products, including revolving credit facilities, and letters of credit and similar financial guarantees.

Anadys Pharmaceuticals, Inc. (Public, NASDAQ:ANDS) increased 11.82%, to close at $1.23 and its overall traded volume was 2.70M shares during the last session against its average volume of 638,148.00. ANDS opened the day at $1.14, it made an intraday low of $1.13 and an intraday high of $1.25. The stock has a 52 week low of $0.90 and 52 week high of $3.24. ANDS’s market capitalization is 70.24M and it has 57.10M outstanding shares.

About Anadys Pharmaceuticals, Inc. (Public, NASDAQ:ANDS)

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing medicines for the treatment of hepatitis C. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C. It has also investigated ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7 (TLR7), pathway in a Phase I trial in hepatitis C. In June 2009, the Company initiated a strategic restructuring to focus its operations on the development of ANA598, in particular the Phase II study of ANA598 in combination with pegylated interferon and ribavirin. As part of the restructuring, it suspended further development of ANA773.

Apricus Bioscience Inc (Public, NASDAQ:APRI) increased 2.86%, to close at $3.95 and its overall traded volume was 2.64M shares during the last session against its average volume of 1.00M. APRI opened the day at $4.15, it made an intraday low of $3.88 and an intraday high of $4.34. The stock has a 52 week low of $1.60 and 52 week high of $12.58. APRI’s market capitalization is 50.77M and it has 12.85M outstanding shares.

About Apricus Bioscience Inc (Public, NASDAQ:APRI)

Apricus Biosciences, Inc., formerly NexMed, Inc., is a pharmaceutical research and development company focused on the design and development of products and technologies in multiple therapeutic areas, including oncology, sexual dysfunction, autoimmune diseases and pain/inflammation. Its drug delivery technology is called NexACT. The Company has two operating segments: designing and developing pharmaceutical products (The NexACT drug delivery technology business) and providing pre-clinical CRO services (The Bio-Quant CRO business). In March 2010, the Company acquired PrevOnco, a marketed anti-ulcer compound, lansoprazole, for the treatment of solid tumors. On December 14, 2009, the Company acquired Bio-Quant, Inc. (Bio-Quant).